# Mountain Crest Acquisition Corp. V > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Mountain Crest Acquisition Corp. V). ## Overview Mountain Crest Acquisition Corp. V is a special purpose acquisition company formed to identify and merge with a private operating business. It has not conducted commercial operations or generated operating revenue; its activity has centered on the IPO trust account, public-company compliance, and pursuing a business combination that was later terminated with AUM Biosciences. ## Products & services • Blank-check acquisition vehicle for a future merger • IPO trust account holding investor proceeds • Sponsor-funded working capital and promissory note support • Public-company listing and transaction execution platform - **SPAC capital vehicle** (100%) — A listed acquisition shell that raises cash in an IPO and seeks a target business to merge with. - Blank-check acquisition vehicle for a future merger - IPO trust account holding investor proceeds - Sponsor-funded working capital and promissory note support - Public-company listing and transaction execution platform ## Customers The company does not sell products or services to end customers in the normal operating sense. Its economic counterparties are public-market investors, the sponsor, underwriters, and any prospective merger target that would become the operating business after a business combination. The terminated AUM Biosciences transaction shows that its core 'customer' relationship is really the negotiation and execution of a de-SPAC deal. - **Public shareholders** (primary) — Investors who purchased IPO units and hold redeemable shares while waiting for a business combination. - **Sponsor** (primary) — Mountain Crest Global Holdings LLC provides capital support and may fund working capital through notes. - **Merger target companies** (primary) — Private operating businesses that may combine with the SPAC to access public markets. - **Underwriters and advisors** (secondary) — Parties that earn fees for the IPO and transaction process, including deferred underwriting commissions. - Public shareholders who buy units and redeem or hold for a deal - Sponsor providing capital, support, and bridge financing - Underwriters receiving deferred fees if a deal closes - Potential merger targets seeking a public listing via SPAC - Advisors and service providers supporting transaction execution ## Geography Mountain Crest Acquisition Corp. V is incorporated and listed in the United States, and its cash management, reporting, and sponsor arrangements are U.S.-based. The only disclosed operating footprint in the excerpts is the cross-border target process, including a Cayman Islands holding company, a Singapore subsidiary, and a Delaware merger sub for the proposed AUM Biosciences transaction. Geography matters mainly because the company’s future business depends on where the eventual target is organized and operates, not on current operating revenue. - United States is the company’s home market and listing base - Trust account and public-company compliance are U.S.-centered - Proposed target structure spanned Cayman Islands, Singapore, and Delaware - No operating revenue geography is disclosed because the company has no operations - Future geography will depend on the acquired business after a merger ## Strategy The company’s strategy is to complete a business combination with a suitable operating target and convert from a shell into an operating public company. The disclosed AUM Biosciences process shows the practical focus: sourcing a target, negotiating terms, obtaining shareholder approval, and managing redemption risk before closing. Until a transaction closes, preserving trust-account value and controlling public-company costs remain the main priorities. - **Complete a business combination** (short-term) — The company has no operating business until it closes a merger with a target. - **Maintain liquidity while searching for a target** (short-term) — The SPAC must fund legal, audit, and diligence costs before any deal closes. - **Protect trust-account value** (short-term) — Trust proceeds are the main source of value for shareholders and deal funding. - Identify and negotiate a viable merger target - Preserve trust-account capital for a future combination - Manage redemption risk and shareholder approval process - Use sponsor support to fund working capital needs - Control public-company and due diligence expenses ## Risks The company’s main risk is that it may fail to complete a business combination, which would leave it without an operating business and could force liquidation. It also faces redemption, financing, and transaction-execution risk because SPAC economics depend on shareholder approvals, target acceptance, and sufficient cash remaining after redemptions. Like other blank-check companies, it is exposed to regulatory, legal, and valuation risk around due diligence, deal terms, and the accounting for redeemable shares and deferred fees. - **Failure to complete a business combination** [critical] — The company has no operating revenues and depends on closing a merger to create value. - **Shareholder redemptions** [high] — High redemptions can shrink trust cash and make a target transaction harder to finance. - **Sponsor and working-capital dependence** [high] — The company relies on sponsor loans and support to cover ongoing expenses. - **Transaction execution and target risk** [high] — The terminated AUM Biosciences deal shows that negotiations can fail even after amendments and proxy filing. - No operating business until a merger closes - Business combination failure can trigger liquidation - Redemptions can reduce cash available for the target - Sponsor and bridge financing may be insufficient - Public-company and transaction costs continue before revenue exists - Deferred underwriting fees are payable only if a deal closes ## Accounting The most important accounting issue is the classification of redeemable common stock, which is recorded outside permanent equity as temporary equity when redemption rights are outside management’s control. The trust account and related interest income also matter because they are the company’s main source of non-operating income, while deferred underwriting commissions are only recognized as payable if a business combination closes. Because the company has no operating revenue, small changes in legal, audit, and due diligence costs can drive reported losses quarter to quarter. - **Common stock subject to possible redemption** — Changes reported equity and can distort leverage-style analysis. - **Trust account interest income** — Offsets operating costs and affects net loss volatility. - **Deferred underwriting commissions** — Creates a contingent transaction cost tied to closing. - **Sponsor promissory note** — Affects liquidity and short-term liabilities. - Redeemable common stock is classified as temporary equity - Trust-account interest income is the main non-operating income source - Deferred underwriting commissions depend on deal completion - Sponsor note and affiliate support affect liquidity and liabilities - Quarterly losses are driven by public-company and diligence expenses --- *Last updated: 2026-09-24T10:47:00.770645+00:00*